Delving into the Latest Updates on Omega-3-acid ethyl esters(Trygg Pharma AS) with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Lotriga Granular, OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS TYPE A

+ [18]

Target

Lipid x Triglyceride

Action

modulators

Mechanism

Lipid modulators, Triglyceride modulators

Therapeutic Areas

Congenital DisordersEndocrinology and Metabolic DiseaseOther Diseases+ [2]

Active Indication

HyperlipidemiasHyperlipoproteinemia Type IHypertriglyceridemia+ [2]

Inactive Indication

Acute myocardial infarctionCarotid StenosisDeath, Sudden, Cardiac+ [2]

Originator Organization

Trygg Pharma AS

Active Organization

BASF Corp.Pronova BioPharma ASAViatris Pty Ltd.

+ [2]

Inactive Organization

Pronova Biopharma Norge ASAllergan UC

Abbott Laboratories Trading (Shanghai) Co. Ltd.

+ [6]

Drug Highest PhaseApproved

First Approval Date

United States (10 Nov 2004),

Hypertriglyceridemia

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC46H70O4

InChIKeyDTMGIJFHGGCSLO-FIAQIACWSA-N

CAS Registry861006-80-6

This phase II trial evaluates tamoxifen, with or without omega-3 fatty acids, for reducing risk of breast cancer among postmenopausal and overweight or obese women who are at increased risk of developing breast cancer. Tamoxifen is a selective estrogen receptor modulator. It works by blocking the effects of the hormone estrogen in the breast. Tamoxifen is approved by the Food and Drug Administration for prevention of breast cancer in women at increased risk. Omega-3 fatty acids have been shown to decrease the amount of fats made in the liver. Omega-3 fatty acids may work to prevent cancer in overweight or obese individuals. Tamoxifen with or without omega-3 fatty acids may be effective at reducing risk of breast cancer among women who are postmenopausal, overweight or obese, and at increased risk.

Start Date26 Aug 2025

Sponsor / Collaborator

National Cancer Institute

ChiCTR2400084087

/ SuspendedPhase 1IIT

Pre IVF/ICSI intake Omega 3 Fatty Acid in PCOS patients:A multicenter, randomized, double-blind, placebo-controlled clinical trial

Start Date01 Jun 2025

Sponsor / Collaborator-

IRCT20240119060733N2

/ SuspendedNot ApplicableIIT

Studying the effect of supplementing with nano-form omega-3 in mothers on controlling cow's milk protein allergy in breastfed children and comparing it with regular omega-3

Start Date20 Jan 2025

Sponsor / Collaborator

Mashhad University of Medical Sciences

100 Clinical Results associated with Omega-3-acid ethyl esters(Trygg Pharma AS)

Login to view more data

100 Translational Medicine associated with Omega-3-acid ethyl esters(Trygg Pharma AS)

Login to view more data

100 Patents (Medical) associated with Omega-3-acid ethyl esters(Trygg Pharma AS)

Login to view more data

5,011

Literatures (Medical) associated with Omega-3-acid ethyl esters(Trygg Pharma AS)

31 Dec 2025·Epigenetics

Alpha-linolenic acid-mediated epigenetic reprogramming of cervical cancer cell lines

Article

Author: Kaul-Ghanekar, Ruchika ; Ulhe, Amrita ; Chaudhary, Amol ; Raina, Prerna

Cervical cancer, the fourth most common cancer globally and the second most prevalent cancer among women in India, is primarily caused by Human Papilloma Virus (HPV). The association of diet with cancer etiology and prevention has been well established and nutrition has been shown to regulate cancer through modulation of epigenetic markers. Dietary fatty acids, especially omega-3, reduce the risk of cancer by preventing or reversing the progression through a variety of cellular targets, including epigenetic regulation. In this work, we have evaluated the potential of ALA (α linolenic acid), an ω-3 fatty acid, to regulate cervical cancer through epigenetic mechanisms. The effect of ALA was evaluated on the regulation of histone deacetylases1, DNA methyltransferases 1, and 3b, and global DNA methylation by ELISA. RT-PCR was utilized to assess the expression of tumor regulatory genes (hTERT, DAPK, RARβ, and CDH1) and their promoter methylation in HeLa (HPV18-positive), SiHa (HPV16-positive) and C33a (HPV-negative) cervical cancer cell lines. ALA increased DNA demethylase, HMTs, and HATs while decreasing global DNA methylation, DNMT, HDMs, and HDACs mRNA expression/activity in all cervical cancer cell lines. ALA downregulated hTERT oncogene while upregulating the mRNA expression of TSGs (Tumor Suppressor Genes) CDH1, RARβ, and DAPK in all the cell lines. ALA reduced methylation in the 5' CpG island of CDH1, RARβ, and DAPK1 promoters and reduced global DNA methylation in cervical cancer cell lines. These results suggest that ALA regulates the growth of cervical cancer cells by targeting epigenetic markers, shedding light on its potential therapeutic role in cervical cancer management.

01 Jun 2025·Journal of Stomatology, Oral and Maxillofacial Surgery

The implications of atorvastatin administration and the potential protective role of omega-3 on the submandibular salivary gland of albino rats (Histological, Histochemical, Ultrastructure, and Biochemical Study)

Article

Author: Gamal, Sherif ; Abd-Elmonsif, Nehad M ; Abd-elmonsif, Nehad M.

BACKGROUNDHyperlipidemia is a risky condition that can lead to atherosclerosis and other cardiovascular problems. Statins are used to treat hyperlipidemia. The most recommended medicine to treat hyperlipidemia is atorvastatin. On the contrary, clinical trials validated statins' negative effects. Omega-3 fatty acids have antioxidant properties and have been shown to improve a variety of disease processes in the general population, including inflammatory and immunological pathways, various cardiovascular diseases, and lipid regulation. The present research aimed to determine how atorvastatin affected the submandibular salivary gland (SMG) and whether omega-3 may have a protective impact.METHODSThirty adult male albino rats were divided into three equal groups and received drugs orally as a single daily dose for one week. Control group (I): received normal saline. Atorvastatin group (II): received a dose of 80 mg Kg^-1 of Atorvastatin. Group III: received Omega-3 before Atorvastatin. All rats were sacrificed 2 h following the last dose, and blood samples were gathered for the biochemical study of fasting blood glucose level (FBGL). Specimens were obtained and processed for histological and histochemical studies.RESULTSAtorvastatin-treated rats showed degeneration of SMG acini. The acinar cells showed cytoplasmic vacuoles with dilated RER. Histochemical results revealed a marked decrease in total proteins. The biochemical study revealed an elevation in FBGL. The administration of Omega-3 with Atorvastatin minimizes these changes.CONCLUSIONAtorvastatin has been proven to induce histological changes in SMG, and these changes can be attenuated by Omega-3. However, Omega-3 has no effect on FBGL.

01 May 2025·Environmental Research

Lake depth influences mercury and omega-3 levels in Walleye via resource utilization shifts

Article

Author: Parmar, Tarn Preet ; Creed, Irena F ; Arts, Michael T ; Strandberg, Ursula ; Bhavsar, Satyendra P

Elevated mercury levels in fish are correlated with their body size and trophic position, and with environmental parameters (e.g., catchment and lake properties). Much less is known how the variation of polyunsaturated fatty acids (PUFA) in fish is intertwined with environmental variables and mercury levels. We studied the linkages between catchment and lake properties and the variation of eicosapentaenoic acid (EPA), docosahexanenoic acid (DHA) and mercury levels in Walleye (Percidae, Sander vitreus) from 30 lakes in the Province of Ontario, Canada. Walleye mercury and DHA levels correlated with fish length; thus, we used length-standardized mass fractions in the correlation analyses of lake and catchment properties and the intraspecific variation of mercury, EPA and DHA in Walleye. Overall, the data indicated that mercury, EPA and DHA levels in Walleye are linked to habitat availability, i.e., relative abundance of pelagic vs. littoral areas, and consequently, to differences of the reliance on pelagic vs. littoral or benthic food webs. The length-standardized mass fractions of mercury, EPA, and DHA increased with increasing maximum depth of a lake, which explained 35% of the total variation. Habitat availability may be integral in determining the foraging grounds and diet selection of Walleye, which in turn is linked with muscle EPA, DHA, and mercury levels, as well as the risk and benefits of consuming Walleye for humans. Thus, the findings have direct applicability to informing lake-specific consumption advisories for Walleye.

62

News (Medical) associated with Omega-3-acid ethyl esters(Trygg Pharma AS)

07 Mar 2025

·www.prnewswire.com

TRANSFORM YOUR SKIN HEALTH: DIET AND LIFESTYLE TAKE CENTER STAGE AT 2025 AAD ANNUAL MEETING

ORLANDO, Fla., March 7, 2025 /PRNewswire/ -- The 2025 American Academy of Dermatology Annual Meeting will take place March 7-11 in Orlando. The meeting will feature nearly 300 educational sessions with more than 1,700 speakers discussing the latest research on skin, hair, and nails, including topics on how diet and lifestyle can transform skin health, eczema management, and insights into aging skin. A New Era in Skin Health: GLP-1 Medications Your skin is often a window to your overall health, including underlying inflammatory and metabolic conditions. New treatments, like GLP-1 medications commonly used for weight loss, can help manage obesity, reduce inflammation, and improve skin conditions, highlighting how board-certified dermatologists are advancing personalized care. Inflammation and Skin Conditions Are Linked: Obesity often causes inflammation that can worsen or trigger skin conditions like psoriasis, eczema, and hidradenitis suppurativa, a chronic disease that causes painful lumps to form under the skin. GLP-1 Medications and Your Skin: While originally developed to treat diabetes and, more recently, promote weight loss, GLP-1 medications can reduce inflammation caused by obesity and improve certain skin conditions. A New Era of Dermatology: Treating conditions like obesity can bring about a healthier 'you' and help skin treatments work better, leading to more complete care. Lindsey Bordone, MD, FAAD, an assistant professor of dermatology at Columbia University Department of Dermatology, can discuss the connection between obesity and skin health, and how addressing your overall health can benefit your skin and well-being. The Role of Diet in Managing Eczema Many people believe that food is the root cause of atopic dermatitis, commonly known as eczema, which can result in dry, itchy skin. However, the relationship between diet and this common skin condition is more complex than it seems. New research is shedding light on how diet influences eczema – which affects nearly one in ten Americans – and empowers patients to make more informed choices. Cutting Foods Isn't a Cure-All: For most patients, simply eliminating certain foods doesn't significantly improve eczema symptoms, despite common misconceptions. The Role of a Healthy Diet: Emphasizing overall healthy eating and avoiding allergens can still play an important role in managing eczema. Early Allergen Introduction: Introducing allergenic foods early in life may help build tolerance, offering a powerful shift in how people manage their eczema. Peter A. Lio, MD, FAAD, a clinical assistant professor of dermatology at Northwestern Medicine in Chicago, can provide evidence-based strategies for managing eczema through diet and lifestyle. How Diet Can Enhance the Effectiveness of Skin Treatments The foods you eat play a vital role in how well medications work for skin conditions and can even help to minimize possible side effects. By making thoughtful dietary choices, you can support your skin health, maximize the effectiveness of treatments for skin disease, and improve your overall health. Optimize Treatment with Nutrition: The Mediterranean diet, which encourages people to eat plant-based foods, and omega-3 fats, can help make biologic treatments for psoriasis more effective, while also reducing heart disease risks associated with this common skin condition. Support Immunotherapy with Fiber: For advanced melanoma, the deadliest form of skin cancer, a diet rich in fiber from fruits, vegetables, and whole grains enhances the effectiveness of immunotherapy, a cancer treatment that uses the patient's own immune system to fight the disease. At the same time, patients should avoid probiotic supplements, which can make treatments less effective. Complement Therapy with Supplements: For those who suffer from acne, omega-3 supplements improve the absorption of isotretinoin, a common acne medication, and minimize its side effects. Steven Daveluy, MD, FAAD, an associate professor of dermatology at Wayne State University in Dearborn, Michigan, details how your diet can work alongside your treatment plan for healthier skin and a healthier you. Understanding Itch: A Window into Aging Skin Itch is the most common symptom for which patients over 50 visit a dermatologist. Importantly, recent scientific breakthroughs and treatment innovations are revolutionizing dermatologists' understanding and management of this condition. More than a symptom, itch offers valuable insights into how the immune system, nervous system, and skin barrier – the outermost layer of skin that serves as a protective shield for the body – change as we age. Increasingly More Common and Severe: Itch becomes more common and severe with age, significantly impacting quality of life, including sleep, daily activities, and our ability to care for others. Complicated Causes in Older Adults: Diagnosing the cause of itch in older adults is harder because visual signs and lab clues are less definitive. This can result in undertreatment. Evolving Treatments: While there are no FDA-approved medications specifically for itch, dermatologists have a variety of treatments at hand to address its effects, including moisturizers as well as topical ointments, phototherapy, biologics – which target diseases throughout your body and neurologic treatments like nerve creams and oral medications. Daniel C. Butler, MD, FAAD, an assistant dean and an associate professor of dermatology at University of Arizona College of Medicine in Tucson, can discuss the types of personalized treatment options dermatologists recommend for patients who struggle with persistent itch. If you have questions about a skin, hair, or nail condition, consult a board-certified dermatologist to ensure you receive trusted, expert guidance tailored to your needs. About the AAD Headquartered in Rosemont, Ill., the American Academy of Dermatology, founded in 1938, is the largest, most influential and most representative of all dermatologic associations. With a membership of more than 21,000 physicians worldwide, the AAD is committed to advancing the diagnosis and medical, surgical, and cosmetic treatment of the skin, hair, and nails; advocating high standards in clinical practice, education and research in dermatology; and supporting and enhancing patient care because skin, hair, and nail conditions can have a serious impact on your health and well-being. For more information, contact the AAD at (888) 462-DERM (3376) or aad.org. Follow @AADskin on Facebook, Pinterest, and YouTube, and @AADskin1 on Instagram. SOURCE American Academy of Dermatology WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

19 Dec 2024

·www.businesswire.com

Marea Therapeutics Expands Management Team and Board of Directors

SAN FRANCISCO--( BUSINESS WIRE )--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardiometabolic diseases, today announced additions to its management team and board of directors. “Momentum continues to build at Marea as we advance our lead program, MAR001, through clinical development,” said Josh Lehrer, M.D., M.Phil., FACC, chief executive officer of Marea. “We are pleased to welcome Rebecca and Max to our leadership team and Robert to our board of directors. Their collective experience and expertise will be important as Marea enters its next phase of growth.” Rebecca Juliano, Ph.D., Appointed as Chief Development Officer Dr. Juliano has been in lipid-related research for more than 25 years and brings to Marea industry leadership experience across clinical program design, execution and communication. Most recently, Dr. Juliano served as chief operating officer at a stealth biotech startup, where she shaped teams and clinical programs for cardiovascular and rare disease indications. Prior to that, she led the clinical and related teams at Amarin Pharma, which were responsible for the cardiovascular outcomes trial REDUCE-IT, which received global approvals, led to changes in at least 15 global clinical guidelines, and received numerous accolades such as being named a top clinical trial by AHA, ACC and NEJM. Dr. Juliano began her industry career at Reliant Pharmaceuticals with the launch of Lovaza, and she has served multiple leadership and transitional consulting roles across her career. Prior to joining industry, Dr. Juliano was an AHA fellow at Weill Cornell Medical Center. She holds a Ph.D. from Columbia University and earned a B.S. in chemistry from the University of California, Santa Cruz. Max Zeiberg Appointed as Senior Vice President, Corporate Development Mr. Zeiberg most recently served as vice president, business development at Sana Biotechnology and at Graphite Bio, where he led partnering, strategic planning, and contributed to Graphite's Series B and IPO financings. Prior to that, Mr. Zeiberg held roles of increasing responsibility on the corporate development team at Gilead Sciences, culminating as head of virology partnering and M&A. During his time at Gilead, he successfully led numerous strategic transactions to build the company’s pipeline. Mr. Zeiberg began his career advising life science companies on commercial strategy and pipeline prioritization as a management consultant with ZS Associates. Mr. Zeiberg holds a B.S. in biomedical engineering from Columbia University and an MBA from the Kellogg School of Management at Northwestern University. Robert A. Harrington, M.D., Appointed to Board of Directors Dr. Harrington is a cardiologist and serves as the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine and provost for medical affairs of Cornell University. His research areas of focus include evaluating antithrombotic therapies to treat acute ischemic heart disease and to minimize the acute complications of percutaneous coronary procedures, and trying to better understand and improve upon the methodology of clinical research, including the use of technologies to facilitate the conduct of clinical trials. Dr. Harrington was the Arthur L. Bloomfield Professor and chair of the Department of Medicine at Stanford University for more than 10 years. He previously served as the Richard Stack Distinguished Professor and the director of the Duke Clinical Research Institute at Duke University, where he completed his fellowship in general and interventional cardiology. Dr. Harrington holds a Bachelor’s degree in English from the College of the Holy Cross and an M.D. from Tufts University School of Medicine. He served as chief resident during his residency in internal medicine at the University of Massachusetts Medical Center in Worcester. About Marea Therapeutics Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardiometabolic diseases. The company’s lead program, MAR001, is in Phase 2 clinical development for adults with metabolic dysfunction and high risk for cardiovascular disease. Marea is led by a dynamic team of scientists and company builders with deep know-how and experience in cardiometabolic diseases, human genetics and adipocyte biology. To learn more, please visit www.mareatx.com and follow us on LinkedIn and X .

Executive ChangePhase 2

05 Nov 2024

·www.drugs.com

Fish Oil Supplements Might Help Prevent Cancer

TUESDAY, Nov. 5, 2024 -- The omega-3 and omega-6 fatty acids in fish oil supplements might help protect people from cancer , a new study claims. Study participants with higher levels of omega-3s had lower rates of colon , stomach, lung and other digestive tract cancers, researchers found. Likewise, high omega-6 levels led to lower rates of 14 different cancers, including brain, melanoma, bladder and more, result showed. “These findings suggest that the average person should focus on getting more of these fatty acids in their diets,” said lead researcher Yuchen Zhang , a doctoral student with the University of Georgia’s College of Public Health. The study relied on data from more than 253,000 participants in the UK Biobank research project. As part of that project, participants filled out dietary questionnaires and had their health tracked for decades. Of those people, nearly 30,000 developed some form of cancer, researchers said. Importantly, the benefits of high levels of fatty acids were independent of other cancer risk factors like BMI, alcohol use or physical activity. These fatty acids are present in fatty fish, nuts and plant-based cooking oils, but many people turn to fish oil supplements to make sure they’re getting enough. However, the benefits of these fatty acids aren’t universal. The researchers noted that high omega-3 levels could be associated with a slightly higher risk of prostate cancer. “For women, it’s an easy decision: Eat more omega-3,” researcher Kaixiong Ye , an associate professor in UGA’s Franklin College of Arts and Sciences, said in a university news release. The new study was published recently in the International Journal of Cancer . Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

100 Deals associated with Omega-3-acid ethyl esters(Trygg Pharma AS)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D05255	Omega-3-acid ethyl esters(Trygg Pharma AS)	C10AX06	DB09539

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hyperlipidemias	Japan	Takeda Pharmaceutical Co., Ltd.	28 Sep 2012
Hyperlipoproteinemia Type I	Australia	Viatris Pty Ltd.	05 Aug 2010
Hypertriglyceridemia	United States	Waylis Therapeutics LLC	10 Nov 2004

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cardiovascular Diseases	Phase 3	United States	Pronova BioPharma ASA	01 Jul 2010
Cardiovascular Diseases	Phase 3	United States	BASF Corp.	01 Jul 2010
Neoplasms	Phase 3	United States	Pronova BioPharma ASA	01 Jul 2010
Neoplasms	Phase 3	United States	BASF Corp.	01 Jul 2010
Acute myocardial infarction	Preclinical	Germany	Pronova BioPharma ASA	01 Oct 2003
Hypertriglyceridemia	Discovery	United States	Osmotica Pharmaceutical US LLC	23 Apr 2014
Hyperlipoproteinemia Type II	Discovery	Norway	Pronova BioPharma ASA	01 Mar 2013
Death, Sudden, Cardiac	Discovery	Germany	Pronova BioPharma ASA	01 Oct 2003
Carotid Stenosis	Discovery	United Kingdom	Pronova BioPharma ASA	01 Aug 2003

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03329248 (QUILT-3.060, CTgov)	Phase 1/2	Pancreatic Cancer	6	SBRT+GI-4000+lovaza+Leucovorin+ETBX-011+fluorouracil+ALT-803+nab-paclitaxel+cyclophosphamide+haNK for infusion+Bevacizumab+Oxaliplatin+Capecitabine	(iliasupzdv) = krrvlzhmww vatifcsxye (utzlaqurel, xugrhvzcvm - sysmsoxust) View more	-	12 Dec 2024
ESC2024	Not Applicable	Cardiovascular Diseases	-	Eicosapentaenoic acid (EPA)	(haejeipktf) = xyaxgphtym vgqtuweciu (fqqdmcmhhy, 0.95 - 0.98)	-	02 Sep 2024
				Docosahexaenoic acid (DHA)	(haejeipktf) = wswacaijhf vgqtuweciu (fqqdmcmhhy, 0.86 - 0.89)
NCT04181593 (CTgov)	Phase 3	Dry Eye Syndromes	322	Omega 3 fatty acid (OmegaD)	siizialcfl(hzfeneiska) = zxzbsdvgsh avnnosezzg (pfjgxssbbp, ltfgibyckk - lyoeyfrhoz) View more	-	29 Jul 2024
				Placebos (Placebo)	siizialcfl(hzfeneiska) = dhqfayobmu avnnosezzg (pfjgxssbbp, ltuxnmzvhg - tygowewvpk) View more
NCT03387098 (P713, CTgov)	Phase 1/2	Pancreatic Cancer	4	SBRT+Aldoxorubicin HCl+GI-4000+lovaza+Leucovorin+ETBX-011+fluorouracil+ALT-803+Nab-paclitaxel+Cyclophosphamide+haNK for infusion+Bevacizumab+Oxaliplatin+Capecitabine	nmrkphiixw(gonbnrbwlm) = zlpqsvpbxm hberrfgefb (almchasgtk, gflmosksgh - lpbqeqnnfo) View more	-	22 May 2024
NCT00746811 (CTgov)	Phase 4	Primary hypercholesterolemia	32	P-OM3 (P-OM3)	dljqrfznzh(xmbidwjqvm) = aebxclmsvz miyuxtnpyz (yvktnkntcr, qdpnyabhyv - myzhxaprra) View more	-	08 May 2024
				Placebo (Placebo)	dljqrfznzh(xmbidwjqvm) = crzwerlhvu miyuxtnpyz (yvktnkntcr, qngdjuzmnh - dtfgonvzji) View more
NCT04198805 (PUVENAFLD, CTgov)	Phase 2	Insulin Resistance \| Nonalcoholic Steatohepatitis \| Hypertension	205	Omega-3 fatty acid+Vitamin E (DHA EE (1.89 g) and Vitamin E (1000 mg))	djsbszgpdy(cbtlctsujt) = egzldnbafd pictndzthl (wzquiwajeq, svxxbyunez - zletosdxsp) View more	-	25 May 2023
				Placebo (Placebo)	djsbszgpdy(cbtlctsujt) = rdqkjueuie pictndzthl (wzquiwajeq, gkacjeqzoi - wisrzvkirr) View more
NCT03345550 (OPTIMA, CTgov)	Phase 2	Brain Concussion	44	Omega-3 Polyunsaturated Fatty Acids (Fish Oil 1000 mg (contains 500 mg DHA & 100 mg EPA)) or placebo capsules. (Omega-3 Polyunsaturated Fatty Acid Treatment Arm)	pkrdfhkcvq(sugbbxhvnm) = svxbdkdmxt qpnuiizrnm (fmzqhplyhd, whgydgbfim - lwlbflakqd) View more	-	23 May 2023
				Placebo - Cap (Placebo Arm)	pkrdfhkcvq(sugbbxhvnm) = bucwuyafla qpnuiizrnm (fmzqhplyhd, dutfhoxxhv - lenrvqheri) View more
NCT01696435 (VITAL \| VITAL-DEP, CTgov)	Not Applicable	Depressive Disorder	18,353	Fish oil placebo+vitamin D3 (Vitamin D + Fish Oil Placebo)	wgoestoaim(uulrlcrewb) = faghuxbyzo fzumsohzta (yxnpaftzgc, kdzbbajort - dmyuiagtfp) View more	-	14 Mar 2023
				Vitamin D placebo+omega-3 fatty acids (fish oil) (Vitamin D Placebo + Fish Oil)	wgoestoaim(uulrlcrewb) = ggrndyycwn fzumsohzta (yxnpaftzgc, ndczeakbst - nqmcmcspzr) View more
NCT04495816 (CTgov)	Phase 2	COVID-19 \| Anosmia	139	Omega-3 Fatty Acid Supplement (Omega-3)	vbhsifwzmo(kvkaviwoig) = imwgddyijx drhxscjrwm (ieuwtsjhgq, ykhkwloctl - lvsnzczsvd) View more	-	31 Jan 2023
				Placebo/Control (Placebo/Control)	vbhsifwzmo(kvkaviwoig) = xgqksgnnts drhxscjrwm (ieuwtsjhgq, fxgerezviq - iwfoauhjxc) View more
NCT00286234 (CTgov)	Phase 4	Hypertriglyceridemia \| Metabolic Syndrome	68	placebo+omacor+niaspan (Dual Placebo)	oylynzzaph(ciwbejyjig) = khhxmchbxa chyuixlvuu (truanhgzjg, oehojcoghc - fmybraived) View more	-	26 Oct 2021
				niacin (Niaspan)	oylynzzaph(ciwbejyjig) = itkeyrjgys chyuixlvuu (truanhgzjg, qiiicwjgsa - dbrjchblxy) View more